The first infusion of an investigational drug that aims to delay or help to prevent the earliest memory loss due to Alzheimer’s disease took place in September at Butler Hospital in Providence, R.I., researchers announced.
Sam Slezak originally set out to become a trainer for professional athletes. Here’s how and why he became a project manager for a landmark national Alzheimer’s study instead.
AHEAD 3-45 is a clinical trial for a treatment aimed at preventing cognitive decline in people with preclinical Alzheimer’s Disease (AD).
RI Chosen as 1 of 5 Sites for First Nationwide Study of Lifestyle Intervention to Reduce Risk of Cognitive Decline
The U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER) is sponsored by the Alzheimer’s Association and is the first such study to be conducted in a large, diverse group of Americans across the United States.
Dr. Daniel Gibbs is on a mission to change attitudes on Alzheimer’s after 13 years living with the disease himself. Here’s the important reason why…
Watch this Alzheimer’s educational video to learn about prevention, symptoms, treatment, resources and research from a panel of Rhode Island experts.
Clinical Trials Aimed at Preventing Alzheimer’s to Begin at Butler Hospital’s Memory and Aging Program
The Memory and Aging Program at Butler Hospital will launch trials of two new treatments aimed at preventing Alzheimer’s in early 2020.
The world’s first participant in an Alzheimer’s prevention study finished his 4 1/2-year clinical trial last month. Here’s what he has to say about the experience.